EU Pandemic Bilthoven Biologicals has been selected by the European Commission for pandemic preparedness, signaling strong credibility and potential for multi-year vaccine supply contracts with EU institutions and allied health programs.

UNICEF Partnerships As a vaccine supplier to UNICEF, the company already has established channels for global procurement and distribution, presenting opportunities to upsell additional vaccines and expand into related immunization programs.

Strategic Partnerships Recent collaborations with Bharat Biotech and ongoing ownership by the Cyrus Poonawalla Group position Bilthoven as a gateway for co-development and cross-supply opportunities across the global vaccine ecosystem.

Diversified Portfolio Product lines cover IPV, DT-IPV, Tetanus, and BCG for bladder cancer, allowing cross-sell to public health purchasers and private healthcare providers seeking integrated vaccination or cancer therapy solutions.

Grow Revenue Revenue remains modest but with strong backing, potential for expansion into larger clinical supply agreements, contract manufacturing for international partners, and long-term service contracts related to vaccine production capacity and quality assurance.